

Tight-junction regulator studied specifically for intestinal permeability. 350mcg, 60 capsules.
For research use only · not for human consumption
Orders are placed, processed, and shipped by Prime Bio Group. Fresno Peptide Lab does not stock or sell product — we may earn a commission at no extra cost to you.
Larazotide acetate (formerly AT-001, Alba Therapeutics) is an oral peptide derived from the zonula occludens toxin secreted by Vibrio Cholera. As a tight junction regulator, it binds to receptors of apical intestinal cells and prevents opening of epithelial intestinal tight junctions induced by bacterial antigens, pro-inflammatory cytokines, or gliadin peptides.
Its mechanism has been supported by in vitro and in vivo studies, making it a suitable candidate to treat celiac disease. Larazotide acetate aids in the restoration of the intestinal barrier function by intervening in the zonulin-mediated signaling pathway, blocking zonulin receptors, preventing tight junction disassembly, and minimizing the increase in intestinal permeability.
Moreover, larazotide acetate is involved in rearranging several tight junction proteins to promote tight junction assembly. Larazotide acetate also plays a role in stimulating tight junction closure. BOTTLE DESIGN MAY VARY LARAZOTIDE COA.
Summary of published preclinical and clinical literature, provided for research context only. Not a claim of efficacy and not medical advice.
Tight-junction regulator studied specifically for intestinal permeability. 350mcg, 60 capsules.
Prime Bio Group supplies Larazotide as capsules. Available options: Single unit at $75.
Yes. Prime Bio Group is a physician-owned lab and provides a certificate of analysis on every batch. A COA reports identity by mass spectrometry and purity by HPLC — if you are not sure how to read one, our guide on reading a certificate of analysis walks through it line by line.